Poddubnyy Denis A, Song In-Ho, Sieper Joachim
Charité - Campus Benjamin Franklin, Rheumatology, Medical Department I, Hindenburgdamm 30, 12200 Berlin, Germany.
Expert Opin Drug Saf. 2008 Jul;7(4):401-9. doi: 10.1517/14740338.7.4.401.
Nonsteroidal anti-inflammatory drugs (NSAIDs) play a crucial role in the treatment of ankylosing spondylitis (AS). Most of the AS patients require a continuous and long-term NSAIDs therapy; therefore the question of NSAIDs safety in this population becomes very important.
to review the safety of celecoxib in ankylosing spondylitis treatment.
The PubMed database was searched using the keywords 'ankylosing spondylitis' and 'celecoxib', with the following extraction of clinical trials investigating efficacy and safety of celecoxib in AS.
RESULTS/CONCLUSIONS: Four clinical trials were found: three randomized controlled trials (RCTs) and one open-label extension of a previous RCT. All RCTs showed a good safety profile for celecoxib treatment in AS, similar to that of nonselective NSAIDs. However, long-term (>or= 1 year) celecoxib safety in AS was not investigated in RCTs. Based on the results of long-term non-AS celecoxib studies, most of the AS patients (because of young age and fewer comorbidities) are probably at low risk for cardiovascular and gastrointestinal complications. Celecoxib showed a good efficacy and safety profile in AS, but further investigations are needed to clarify the long-term safety of celecoxib in this group of patients.
非甾体抗炎药（NSAIDs）在强直性脊柱炎（AS）的治疗中起着关键作用。大多数AS患者需要持续且长期的NSAIDs治疗；因此，NSAIDs在该人群中的安全性问题变得非常重要。
综述塞来昔布在强直性脊柱炎治疗中的安全性。
使用关键词“强直性脊柱炎”和“塞来昔布”检索PubMed数据库，随后提取调查塞来昔布在AS中的疗效和安全性的临床试验。
结果/结论：共找到四项临床试验：三项随机对照试验（RCT）和一项先前RCT的开放标签扩展试验。所有RCT均显示塞来昔布治疗AS具有良好的安全性，与非选择性NSAIDs相似。然而，RCT中未对AS患者使用塞来昔布的长期（≥1年）安全性进行研究。基于塞来昔布在非AS患者中的长期研究结果，大多数AS患者（由于年龄较轻且合并症较少）可能发生心血管和胃肠道并发症的风险较低。塞来昔布在AS中显示出良好的疗效和安全性，但需要进一步研究以阐明塞来昔布在该组患者中的长期安全性。
